

Resource Summary Report

Generated by NIF on Jul 28, 2026

beta-Catenin Antibody (Carboxy-terminal Antigen)

RRID:AB_10695312

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9587, RRID:AB_10695312

Antibody Information

URL: http://antibodyregistry.org/AB_10695312

Proper Citation: Cell Signaling Technology Cat# 9587, RRID:AB_10695312

Target Antigen: beta-Catenin (Carboxy-terminal Antigen)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP, IHC-P, IHC-F, ChIP. Consolidation on 11/2018: AB_10695312, AB_10827874, AB_490892.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: beta-Catenin Antibody (Carboxy-terminal Antigen)

Description: This polyclonal targets beta-Catenin (Carboxy-terminal Antigen)

Target Organism: b, c, dg, rat, porcine, h, canine, hr, m, horse, mouse, r, pg, x, bovine, human, mk

Antibody ID: AB_10695312

Vendor: Cell Signaling Technology

Catalog Number: 9587

Record Creation Time: 20250820T022855+0000

Record Last Update: 20250820T134227+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for beta-Catenin Antibody (Carboxy-terminal Antigen).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Shao YY, et al. (2025) Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma. *Biology direct*, 20(1), 49.

Mosialou I, et al. (2025) A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies. *Cancer cell*, 43(6), 1007.

Zhang W, et al. (2024) Decreased extrasynaptic γ -GABAA receptors in PNN-associated parvalbumin interneurons correlates with anxiety in APP and tau mouse models of Alzheimer's disease. *British journal of pharmacology*, 181(20), 3944.

Zhang M, et al. (2022) CDK14 inhibition reduces mammary stem cell activity and suppresses triple negative breast cancer progression. *Cell reports*, 40(11), 111331.

Favaloro F, et al. (2022) miR-17-92 exerts stage-specific effects in adult V-SVZ neural stem cell lineages. *Cell reports*, 41(10), 111773.

Pan R, et al. (2022) RSPO2 promotes progression of ovarian cancer through dual receptor-mediated FAK/Src signaling activation. *iScience*, 25(10), 105184.

Lee R, et al. (2022) Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC-Mutated Colorectal Cancer. *Cancer discovery*, 12(7), 1702.

Zhao D, et al. (2021) Scribble sub-cellular localization modulates recruitment of YES1 to regulate YAP1 phosphorylation. *Cell chemical biology*, 28(8), 1235.

Zhou X, et al. (2019) YAP Aggravates Inflammatory Bowel Disease by Regulating M1/M2 Macrophage Polarization and Gut Microbial Homeostasis. *Cell reports*, 27(4), 1176.

Kim MJ, et al. (2018) PAF-Myc-Controlled Cell Stemness Is Required for Intestinal Regeneration and Tumorigenesis. *Developmental cell*, 44(5), 582.